An interventional study of STN-DBS ON and STN-DBS OFF in Epilepsy, Drug Resistant, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing — 11 open to participants now, 12 under way, none of them phase 3. Drug Resistant Epilepsy · Xuanwu Hospital, Beijing.
Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 12 that started in 2024, is one of 10 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 1st registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →11 of the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 14–60
Xuanwu Hospital, Beijing · Sites in China
Ages 18–60
Xuanwu Hospital, Beijing · Sites in China
Ages 6–60
Xuanwu Hospital, Beijing · Sites in China
Ages 14–65
Xuanwu Hospital, Beijing · Sites in China
Ages 14–65
By country, each count listing its studies:
Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.
This study: 14 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2024; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 33 is close to the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.
Median enrollment 13 across the 12 interventional studies, 30 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.
1 of the studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07305311Xuanwu Hospital, BeijingCharacterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG | 2027-01-08 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of subthalamic nucleus (STN) as adjunctive therapy for reducing the frequency of seizures in drug-resistant focal motor epilepsy.
This is a multicenter, randomized, double-blind, sham-controlled, parallel-group trial that aims to investigate the efficacy of STN-DBS in reducing the frequency of seizures in drug-resistant focal motor epilepsy. Participants who were eligible for the inclusion criteria and ineligible for the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio. The primary purpose of this study is to compare active STN-DBS with sham STN-DBS in reducing seizure frequency. Both intent analysis (ITT) and compliance program set (PPS) were used for analysis. Only high-volume centers with a proven track record will be included. The STEM trial will be conducted in 5 sites in China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with focal motor epilepsy, which meets the following items:
Within 1 month prior to the Screening Visit (M-3), the following conditions are met:
Within the baseline period (3 months after the Screening Visit [M-3]), the following conditions are met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After randomization, participants will undergo STN-DBS ON in the 3-month blinded phase (Month 2 to Month 5) with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
Device: STN-DBS ON
After randomization, participants will undergo STN-DBS OFF in the 3-month blinded phase (Month 2 to Month 5) with 0mA current, then the stimulator will be turned on with individual stimulation parameters and left on for the remainder of the study.
Device: STN-DBS OFF
Stimulation ON
Stimulation OFF
Median Percent Change in Seizure Frequency
Seizure frequency (SF28) is defined as seizure count per month (28-day) period. The SF28 is calculated as follows, where D=total number of days for which seizure information is collected for the specific 28-day interval: SF28=(Total number of seizures in D days/D)\*28. In addition, the baseline seizure frequency is defined as mean of 3-month SF28 in the baseline period. The seizure frequency in double-blind phase is defined as SF28 per month during the double-blind period. Percent change in seizure frequency=100\*(double-blind SF28-baseline SF28)/baseline SF28.
Time frame: Through the end of the three-month blinded phase
Seizure Responder Rate
The proportion of patients with a ≥ 50% reduction from Baseline in seizure frequency.
Time frame: Through the end of the three-month blinded phase
Seizure Severity
The percent change from baseline in seizure severity evaluated by Liverpool seizure severity scale (LSSS) across the double-blind period.
Time frame: Through the end of the three-month blinded phase
Seizure-free Days
Change in percentage of seizure-free days over the entire blinded phase as compared to the entire baseline phase. The number of seizure-free days was normalized to 84-day baseline and blinded phases for each subject.
Time frame: Through the end of the three-month blinded phase
The maximum length of seizure-free Intervals
Percentage change in the maximum length of seizure-free intervals over the entire blinded phase as compared to the entire baseline phase.
Time frame: Through the end of the three-month blinded phase
Life quality evaluation
Percentage change from baseline in Quality of Life in Epilepsy-31 inventory (QOLIE-31) score at 3 months after randomization.
Time frame: Through the end of the three-month blinded phase
Motor function evaluation
Percentage change from baseline in Unified Parkinson's Disease Rating Scale part II \& part III (UPDRS II-III) score at 3 months after randomization.
Time frame: Through the end of the three-month blinded phase
Cognitive function evaluation (MMSE)
Percentage change from baseline in Mini-Mental State Examination (MMSE) score at 3 months after randomization.
Time frame: Through the end of the three-month blinded phase
Cognitive function evaluation (MoCA)
Percentage change from baseline in Montreal Cognitive Assessment (MoCA) score at 3 months after randomization.
Time frame: Through the end of the three-month blinded phase
Psychologic Evaluation (Anxiety)
Percentage change from baseline in Hamilton Anxiety Rating Scale (HAMA) score at 3 months after randomization.
Time frame: Through the end of the three-month blinded phase
Psychologic Evaluation (Depression)
Percentage change from baseline in Hamilton Depression Rating Scale (HAMD) score at 3 months after randomization.
Time frame: Through the end of the three-month blinded phase
Sleep Quality
Percentage change from baseline in Pittsburgh Sleep Quality Index (PSQI) score at 3 months after randomization.
Time frame: Through the end of the three-month blinded phase
Adverse Events
Rate of adverse events which were judged to be study-related throughout the study.
Time frame: Through Month 11 of the open-label follow-up phase
Incidence of Sudden Unexpected Death in Epilepsy (SUDEP)
The number presented is for Definite and Probable SUDEP. The rate is calculated per 1000 subject years of follow-up.
Time frame: Through Month 11 of the open-label follow-up phase
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Dec 2025, 22 months after the start.
Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 22 months is below that.
Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.